Biomolecular interactions between human recombinant beta-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy.

OBJECTIVE Cardiac myosin-binding protein C (cMyBP-C) is a component of sarcomere that contains at least three putative myosin-binding sites. Mutations in its gene are implicated in familial hypertrophic cardiomyopathy (FHC) and most of them are predicted to produce C-terminal truncated cMyBP-Cs. The aim of the present study was to analyze whether cMyBP-C truncated mutants resulting from FHC mutations interact in vitro with human beta-MyHC. METHODS Recombinant proteins were produced using the baculovirus/insect cell system, and wild type and three truncated cMyBP-Cs were purified using metal affinity chromatography. The interaction between recombinant proteins was analyzed in real time using biosensor technology on immobilized anti-beta-MyHC antibodies. RESULTS Biomolecular interaction with beta-MyHC was detected for both wild type cMyBP-C and a truncated mutant lacking half of the C-terminal C10 domain. In contrast, no interaction with beta-MyHC was found for two truncated cMyBP-Cs lacking at least the C5-C9 region. CONCLUSIONS Biosensor technology allows in vitro analysis of the interaction between human beta-MyHC and cMyBP-C mutants resulting from FHC mutations. The data show that the interaction depends on the size of the truncation. This suggests that, in the context of FHC, impairment of suitable interaction between beta-MyHC and some of the truncated cMyBP-Cs may promote degradation of the truncated proteins and therefore contribute to the development of the disease.

[1]  D. Fischman,et al.  The C-terminal IgI domains of myosin-binding proteins C and H (MyBP-C and MyBP-H) are both necessary and sufficient for the intracellular crosslinking of sarcomeric myosin in transfected non-muscle cells. , 2002, Journal of cell science.

[2]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[3]  D. Faxon.  AHA journals lead with definitive new online site. , 1998, Circulation research.

[4]  F. E. Weber,et al.  The major myosin-binding domain of skeletal muscle MyBP-C (C protein) resides in the COOH-terminal, immunoglobulin C2 motif , 1993, The Journal of cell biology.

[5]  T. Mikawa,et al.  Isoform-specific Interaction of the Myosin-binding Proteins (MyBPs) with Skeletal and Cardiac Myosin Is a Property of the C-terminal Immunoglobulin Domain* , 1997, The Journal of Biological Chemistry.

[6]  M. Ikebe,et al.  Functional analysis of the mutations in the human cardiac beta-myosin that are responsible for familial hypertrophic cardiomyopathy. Implication for the clinical outcome. , 1996, The Journal of clinical investigation.

[7]  B. Hambly,et al.  Functional and spectroscopic studies of a familial hypertrophic cardiomyopathy mutation in Motif X of cardiac myosin binding protein-C , 2002, European Biophysics Journal.

[8]  M. Komajda,et al.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. , 1997, Circulation research.

[9]  L. Leinwand,et al.  COOH-terminal truncated human cardiac MyBP-C alters myosin filament organization. , 2001, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[10]  J. Beckmann,et al.  Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[11]  Teruyuki Nagamune,et al.  Observation of charge state and conformational change in immobilized protein using surface plasmon resonance sensor. , 2001, Analytical biochemistry.

[12]  Janet M. Allen,et al.  Use of GPI‐anchored proteins to study biomolecular interactions by surface plasmon resonance , 1998, FEBS letters.

[13]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[14]  J. S. Davis,et al.  Assembly processes in vertebrate skeletal thick filament formation. , 1988, Annual review of biophysics and biophysical chemistry.

[15]  S. Winegrad.  Myosin binding protein C, a potential regulator of cardiac contractility. , 2000, Circulation research.

[16]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[17]  S. Winegrad.  Cardiac myosin binding protein C. , 1999, Circulation research.

[18]  L. Leinwand,et al.  Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. , 1994, The Journal of biological chemistry.

[19]  R. Starr,et al.  Polypeptide chains of intermediate molecular weight in myosin preparations , 1971, FEBS letters.

[20]  H. Watkins.  Genetic clues to disease pathways in hypertrophic and dilated cardiomyopathies. , 2003, Circulation.

[21]  R. Starr,et al.  The interaction of C-protein with heavy meromyosin and subfragment-2. , 1978, The Biochemical journal.

[22]  B. Hainque,et al.  COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes. , 1999, Journal of molecular biology.

[23]  M. Gautel,et al.  A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. , 2000, Circulation.

[24]  C. Seidman.  Genetic causes of inherited cardiac hypertrophy: Robert L. Frye Lecture. , 2002, Mayo Clinic proceedings.

[25]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[26]  J. Koretz.  Structural studies of synthetic filaments prepared from column-purified myosin. , 1979, Biophysical journal.

[27]  M. Gautel,et al.  Mutations in beta-myosin S2 that cause familial hypertrophic cardiomyopathy (FHC) abolish the interaction with the regulatory domain of myosin-binding protein-C. , 1999, Journal of molecular biology.

[28]  W. Rottbauer,et al.  Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. , 1997, The Journal of clinical investigation.

[29]  B. Hainque,et al.  Familial hypertrophic cardiomyopathy: from mutations to functional defects. , 1998, Circulation research.

[30]  Julien S. Davis.  Interaction of C-protein with pH 8.0 synthetic thick filaments prepared from the myosin of vertebrate skeletal muscle , 1988, Journal of Muscle Research & Cell Motility.

[31]  L. Leinwand,et al.  Modulation of myosin filament organization by C-protein family members. , 1996, Molecular biology of the cell.

[32]  F. Reinach,et al.  The interface between MyBP-C and myosin: site-directed mutagenesis of the CX myosin-binding domain of MyBP-C , 1999, Journal of Muscle Research & Cell Motility.

[33]  H. Watkins,et al.  Identification of Novel Interactions Between Domains of Myosin Binding Protein-C That Are Modulated by Hypertrophic Cardiomyopathy Missense Mutations , 2002, Circulation research.

[34]  R. Starr,et al.  Interaction of C-protein with myosin, myosin rod and light meromyosin. , 1975, Journal of molecular biology.